Frontiers in Cell and Developmental Biology · Nov 12, 2026
Placental Senescence in Fetal Growth Restriction: Molecular Mechanisms, Biomarkers, and Therapeutic Implications
By Min Li, Xin Luo, Hongbo Qi
Fetal growth restriction (FGR) affects 5-10% of pregnancies and is a leading cause of perinatal morbidity and mortality, with long-term neurodevelopmental, metabolic, and cardiovascular consequences. Placental insufficiency is the primary etiology, and accumulating evidence identifies premature trophoblast senescence as a central pathogenic mechanism. Senescent trophoblasts exhibit p53/p21-and p16/Rb-mediated cell cycle arrest, a pro-inflammatory senescence-associated secretory phenotype (SASP), telomere attrition with DNA damage, epigenetic aging, and mitochondrial dysfunction driven by a cyclophilin D (CypD)/mitochondrial permeability transition pore (mPTP) self-amplifying reactive oxygen species (ROS) loop, together with impaired autophagy. Upstream drivers include oxidative stress, mitochondrial failure, advanced maternal age, and paracrine SASP/immune amplification, whereas downstream consequences impair trophoblast invasion, syncytiotrophoblast nutrient transport, and placental vascularization, restricting fetal growth. Senescence markers hold translational promise as diagnostic and prognostic biomarkers, and emerging senolytic, senomorphic, and mitochondrial-targeted therapies represent potential interventions. This review critically synthesizes recent evidence, provides a framework linking placental senescence to FGR pathogenesis, identifies key knowledge gaps, and highlights novel therapeutic avenues to improve pregnancy outcomes.